Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
I think particularly with immunotherapy trials there is a tail to the trial which consists of data gathering and analysis?
Whilst we know the Covidity phase 1 trial has indeed ‘ended’ ie no longer recruiting, the conclusions from the data (if any) are still being sought ?
But the modi1 and Scib1 trials are on going .
Would indeed be great to get an update soon though on one or all ?
Take care ..
Morning ! Now that would be something !
I must say this period of quiet is intriguing!? We know there is quite a bit of news due !?
Also .. I was a bit underwhelmed by what has come out of the JP Healthcare conference this year .. ?
Take care all ..
April 22 .. so more updates due soon ..
https://www.trinitydelta.org/research-notes/a-fresh-impetus-in-delivering-immune-oncology-vaccines/
Take care all ..
Konar .. quote from the trinity delta report ..
“ The AvidiMab platform is being employed to increase effectiveness, and extend the patent life, of the Immunobody programmes.”
It’s quite an in depth report and I’m sure most of you will have read it.
Thanks for the comments berm ..
Moditope was a serendipitous discovery .. I think the human eye is more likely to come across such things than AI ? But that’s only my opinion.
Take care all ..
It’s intriguing isn’t it … what are all these AI machines and computers looking for !?
Biological processes that are occurring within cancer cells that the immune system could recognise perhaps?
Also .. that AI is all the rage , suggests to me that they all haven’t found anything yet ?
Just some thoughts as ever ..
Take care all ..
Referring to this From cleaners link this morning ..
“ At the 2023 J.P. Morgan Healthcare Conference Tuesday, CEO Ugur Sahin, M.D., disclosed that the company was working on a modified COVID vaccine that combined the spike protein seen in past versions with T-cell enhancers. ”
Sorry for any confusion ?
Take care ..
Personally, I think even if anyone can make a spike protein vaccine ‘stronger’ , it doesn’t get round the issue of variation ?
Just a thought as ever?
Take care all ..
So t-cell targeting is on the agenda for biontech .. of course as we know it’s not a simple task .. any old t-cell won’t do .. they have to be highly specific and of high avidity to be effective .. we know a company already doing that don’t we !?
Take care .